Improved survival rate and minimal side effects of doxorubicin for lung metastasis using engineered discoidal polymeric particles-Reference-Cited by-同舟云学术

Improved survival rate and minimal side effects of doxorubicin for lung metastasis using engineered discoidal polymeric particles

Published:2022 Issue:15 Volume:10 Page:4335-4344
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Park Sanghyo¹,Park Hyungkyu¹,Park Chaewon¹,Yun Wan Su²³,Hwang Soonjae⁴⁵,Yoon Hong Yeol²³,Kwon Ick Chan²³,Kim Kwangmeyung²³^ORCID,Key Jaehong¹^ORCID

Affiliation:

1. Department of Biomedical Engineering, Yonsei University, Wonju 26493, Republic of Korea

2. KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea

3. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea

4. Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, College of Medicine, Gachon University, Incheon 21999, Korea

5. Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea

Abstract

Schematic illustration of the synthesis of DOX-DPPs. Improving the therapeutic effect of lung cancer requires the development of a drug delivery system that is intensively delivered to the lungs and effective release of the drug from its location.

Funder

National Research Foundation of Korea

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D2BM00718E

Reference43 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer

3. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

4. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy